FDA Approves First Targeted Therapy for NSCLC With KRAS Mutations

FRIDAY, June 4, 2021 -- Lumakras (sotorasib) received the first approval for a targeted therapy in adults with non-small cell lung cancer with KRAS G12C genetic mutations, the U.S. Food and Drug Administration announced on May 28. KRAS G12C...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news